Ontak (Denileukin diftitox) for Lymphoma

Overview
Ontak is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat certain adults with persistent or recurrent cutaneous T-cell lymphoma. Ontak is also referred to by its drug name, denileukin diftitox.

Ontak is a member of a class of drugs called cytotoxins. Ontak is believed to work by destroying cancer cells.

How do I take it?
Prescribing information states that Ontak is administered as an intravenous infusion for five consecutive days every 21 days for eight cycles.

Ontak comes in the form of an injectable solution.

Side effects
The FDA-approved label for Ontak lists common side effects including fever, nausea, vomiting, fatigue, headache, swelling, chills, diarrhea, cough, itching, and trouble breathing.

Rare but serious side effects listed for Ontak include infusion reactions, a serious condition called capillary leak syndrome that can lead to a sharp drop in blood pressure, and blurry vision or vision loss.

For more details about this treatment, visit:

Ontak — RxList
https://www.rxlist.com/ontak-drug.htm